Ed Mathers

Ed is a general partner at New Enterprise Associates (NEA) where he has invested in multiple companies with successful exits including Lumena (acquired by Shire), Ziarco (acquired by Novartis), Motus Therapeutics (acquired by Allergan), and Plexxikon (acquired by Daiichi Sankyo). Before joining NEA, Ed was Executive Vice President, Corporate Development and Venture at MedImmune and part of the leadership team that sold the company to AstraZeneca for $15.6 billion. Prior to MedImmune, he held roles of increasing responsibility at Inhale Therapeutic Systems and at Glaxo Wellcome. Ed is a Board member of multiple biotech and pharmaceutical companies, including gene therapy companies Akouos and Shape Therapeutics. He received his B.S. in Chemistry from North Carolina State University.